Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
08.04. | CHIMERIC THERAPEUTICS LIMITED: Change of Director's Interest Notice PH | - | ASX | ||
08.04. | CHIMERIC THERAPEUTICS LIMITED: Change of Director's Interest Notice PH | - | ASX | ||
05.04. | Chimeric Therapeutics secures US patent for groundbreaking 'killer cell' cancer therapy | 1 | smallcaps.com.au | ||
04.04. | CHIMERIC THERAPEUTICS LIMITED: US patent allowed for CHM 0201 (CORE-NK) technology | - | ASX | ||
02.04. | CHIMERIC THERAPEUTICS LIMITED: Notification of cessation of securities - CHM | - | ASX | ||
28.03. | CHIMERIC THERAPEUTICS LIMITED: Notice under section 708A | - | ASX | ||
28.03. | CHIMERIC THERAPEUTICS LIMITED: Application for quotation of securities - CHM | - | ASX | ||
14.03. | Chimeric Therapeutics highlights key cell therapy targets in treatment of various cancers | 1 | smallcaps.com.au | ||
14.03. | Stocks of the Hour: PainChek, Chimeric Therapeutics, Torque Metals | 1 | Finance News Network | ||
13.03. | CHIMERIC THERAPEUTICS LIMITED: Clinical milestones for 2024 & 2023 successes highlighted | - | ASX | ||
13.03. | CHIMERIC THERAPEUTICS LIMITED: Chimeric to present at NWR Virtual Healthcare Conference | - | ASX | ||
07.03. | CHIMERIC THERAPEUTICS LIMITED: Notification of cessation of securities - CHM | 1 | ASX | ||
01.03. | Chimeric Therapeutics - Webinar Presentation | 1 | Finance News Network | ||
28.02. | CHIMERIC THERAPEUTICS LIMITED: Notice under section 708A | - | ASX | ||
28.02. | CHIMERIC THERAPEUTICS LIMITED: Application for quotation of securities - CHM | - | ASX | ||
27.02. | CHIMERIC THERAPEUTICS LIMITED: Half Yearly Report and Accounts | - | ASX | ||
26.02. | CHIMERIC THERAPEUTICS LIMITED: Chimeric to present at ShareCafe Hidden Gems webinar | - | ASX | ||
15.02. | CHIMERIC THERAPEUTICS LIMITED: Late lodgement of Appendix 3Y | 2 | ASX | ||
08.02. | Chimeric Therapeutics treats first patient in Advent-AML phase 1B clinical trial | - | The Market Herald Australia | ||
08.02. | Stocks of the Hour: QX Resources, Chimeric Therapeutics, Alliance Nickel | 1 | Finance News Network |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 9,235 | +0,82 % | Evotec nach Zahlen: Aktie rauscht ans MDAX-Ende | Der Pharmawirkstoffforscher Evotec hat am Mittwoch seine Zahlen für 2023 vorgelegt. Der Konzern musste einen schwerwiegenden Hackerangriff verkraften und konnte die Erwartungen der Analysten nicht erfüllen.... ► Artikel lesen | |
QIAGEN | 38,760 | +2,16 % | Biotech Report: Sektor fester - Evotec und Qiagen können zulegen | (shareribs.com) Frankfurt / New York 22.04.2024 - Biotech-Aktien verzeichneten zum Wochenauftakt im deutschen Handel Kursgewinne. Gesucht waren unter anderem Evotec und Qiagen. Auch an der Wall Street... ► Artikel lesen | |
CULLINAN THERAPEUTICS | 25,300 | +31,43 % | PEGY, CGEM and IFBD among mid-day movers | ||
RECURSION PHARMACEUTICALS | 8,120 | +3,57 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
CABALETTA BIO | 11,010 | -9,61 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 45,530 | +3,01 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
IMMUNOVANT | 27,170 | -2,09 % | Should You Hold Immunovant (IMVT)? | ||
KEROS THERAPEUTICS | 57,86 | +6,77 % | Prozessmanagement in der Gemeinschaftsverpflegung / Keros Consult optimiert Warenwirtschaft für Eichhof-Stiftung Lauterbach | Düsseldorf (ots) - Ab sofort unterstützt Keros Consult, eine hundertprozentige Tochtergesellschaft der Klüh-Gruppe, die Eichhof-Stiftung Lauterbach bei der Optimierung ihrer Bestell- und Produktionsprozesse... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 24,360 | +2,22 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
DYNE THERAPEUTICS | 24,730 | +4,37 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
ARCELLX | 51,92 | +1,05 % | Should You Be Bullish on Arcellx (ACLX)? | ||
DAY ONE BIOPHARMACEUTICALS | 14,920 | +12,94 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
BIONTECH | 82,40 | +2,11 % | Aufholjagd BioTech 2024 - jetzt positionieren! Bayer, BioNTech, Defence Therapeutics, Evotec, BioNxt und Vidac Pharma im Fokus | BioTech-Investoren haben im Jahr 2024 bislang noch keine große Party feiern können. Das blieb eher den Spekulanten in den Sektoren Künstliche Intelligenz und Rüstung vorbehalten. Doch nun neigen sich... ► Artikel lesen | |
KYMERA THERAPEUTICS | 33,370 | +0,06 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) | ||
NUVALENT | 66,86 | +1,20 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen |